[go: up one dir, main page]

EA200701901A1 - Нуклеиновые кислоты, связывающие грелин - Google Patents

Нуклеиновые кислоты, связывающие грелин

Info

Publication number
EA200701901A1
EA200701901A1 EA200701901A EA200701901A EA200701901A1 EA 200701901 A1 EA200701901 A1 EA 200701901A1 EA 200701901 A EA200701901 A EA 200701901A EA 200701901 A EA200701901 A EA 200701901A EA 200701901 A1 EA200701901 A1 EA 200701901A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fragment
box
greeline
nucleic acids
acids binding
Prior art date
Application number
EA200701901A
Other languages
English (en)
Inventor
Флориан ЯРОШ
Дирк ОЙЛБЕРГ
Кристиан Маш
Штеффен Хельмлинг
Свен КЛУССМАНН
Original Assignee
Нокссон Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нокссон Фарма Аг filed Critical Нокссон Фарма Аг
Publication of EA200701901A1 publication Critical patent/EA200701901A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Настоящее изобретение относится к нуклеиновой кислоте, предпочтительно связывающейся с грелином, где нуклеиновая кислота включает первый фрагмент Бокс А и второй фрагмент Бокс В, где первый фрагмент Бокс А содержит приблизительно 25 последовательных нуклеотидов, второй фрагмент Бокс В содержит приблизительно шесть-восемь последовательных нуклеотидов, где 3'-концевой фрагмент нуклеотидов первого фрагмента Бокс А гибридизуется со вторым фрагментом Бокс В, причем при гибридизации образуется первая двухнитевая структура, где такая первая двухнитевая структура содержит петлю.
EA200701901A 2005-04-08 2006-04-10 Нуклеиновые кислоты, связывающие грелин EA200701901A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05007795 2005-04-08
PCT/EP2006/003276 WO2006108599A2 (en) 2005-04-08 2006-04-10 Ghrelin binding nucleic acids

Publications (1)

Publication Number Publication Date
EA200701901A1 true EA200701901A1 (ru) 2008-04-28

Family

ID=37087373

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701901A EA200701901A1 (ru) 2005-04-08 2006-04-10 Нуклеиновые кислоты, связывающие грелин

Country Status (24)

Country Link
US (2) US8101734B2 (ru)
EP (1) EP1866412A2 (ru)
JP (2) JP5308813B2 (ru)
KR (1) KR20080009072A (ru)
CN (1) CN101189337B (ru)
AP (1) AP2007004189A0 (ru)
AR (1) AR052741A1 (ru)
AU (1) AU2006233647A1 (ru)
BR (1) BRPI0608180A2 (ru)
CA (1) CA2605377A1 (ru)
CR (1) CR9423A (ru)
DO (1) DOP2006000085A (ru)
EA (1) EA200701901A1 (ru)
GB (1) GB2439673A (ru)
GT (1) GT200600137A (ru)
IL (1) IL186085A0 (ru)
MA (1) MA29384B1 (ru)
MX (1) MX2007012419A (ru)
NL (2) NL1031538C2 (ru)
PE (1) PE20061358A1 (ru)
TN (1) TNSN07375A1 (ru)
TW (1) TW200718781A (ru)
UY (1) UY29460A1 (ru)
WO (1) WO2006108599A2 (ru)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1530635B1 (en) * 2002-08-01 2011-06-15 Noxxon Pharma AG Ghrelin binding nucleic acids
CN1894407A (zh) * 2003-11-10 2007-01-10 诺松制药股份公司 特异性结合生物活性生长素释放肽的核酸
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin
EP2274331B1 (en) 2008-05-02 2013-11-06 Novartis AG Improved fibronectin-based binding molecules and uses thereof
US8796216B2 (en) * 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
ES2748038T3 (es) 2011-07-01 2020-03-12 Ngm Biopharmaceuticals Inc Composiciones, usos y métodos para el tratamiento de trastornos y enfermedades metabólicos
EP2925775B1 (en) 2012-11-28 2020-09-16 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
EP2938740B1 (en) 2012-12-27 2022-04-20 NGM Biopharmaceuticals, Inc. Chimeric fgf19 peptides for use in treating bile acid disorders
RU2679889C2 (ru) 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
WO2015031316A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN105848674A (zh) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
MX2017004983A (es) 2014-10-22 2017-11-13 Armo Biosciences Inc Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
IL251834B2 (en) 2014-10-23 2023-09-01 Ngm Biopharmaceuticals Inc Pharmaceutical compositions containing peptide variants and methods of using them
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016187508A2 (en) 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
JP7121496B2 (ja) 2015-05-28 2022-08-18 アルモ・バイオサイエンシーズ・インコーポレイテッド 癌治療で使用するためのペグ化インターロイキン－１０
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
ES2871036T3 (es) 2015-11-09 2021-10-28 Ngm Biopharmaceuticals Inc Método para el tratamiento de trastornos relacionados con ácidos biliares
US20190307868A1 (en) 2016-03-31 2019-10-10 Neon Therapeutics, Inc. Neoantigens and methods of their use
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
BR112019016657A2 (pt) 2017-02-12 2020-04-07 Neon Therapeutics, Inc. métodos baseados em hla e composições e usos destes
CN111315398A (zh) 2017-11-10 2020-06-19 阿尔莫生物科技股份有限公司 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
US20210347842A1 (en) 2018-06-19 2021-11-11 Eli Lilly And Company Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
AU2019365382B2 (en) 2018-10-24 2024-02-08 F. Hoffmann-La Roche Ag Process for the purification of oligonucleotides
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
SG11202106678PA (en) 2018-12-21 2021-07-29 Biontech Us Inc Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
JP7726067B2 (ja) * 2019-06-11 2025-08-20 味の素株式会社 ペプチド及びその用途
JP2022536695A (ja) 2019-06-12 2022-08-18 ビオンテック ユーエス インコーポレイテッド 新抗原組成物およびその使用
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
WO2022032228A1 (en) 2020-08-07 2022-02-10 The Broad Institute, Inc. Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex
CN117083081A (zh) 2020-12-14 2023-11-17 百欧恩泰美国公司 用于癌症免疫疗法的组织特异性抗原
EP4598949A1 (en) 2022-10-07 2025-08-13 The General Hospital Corporation Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614395A (en) * 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
ATE318832T1 (de) * 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
JPH11505527A (ja) 1995-05-03 1999-05-21 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 鏡像異性体リガンドの同定
DE19808591C2 (de) 1998-02-28 2000-02-03 Univ Leipzig Standardisierter durchflußzytometrischer Vollblutassay
US20030211967A1 (en) * 2001-05-07 2003-11-13 Bryant Henry Uhlman Method for selectively inhibiting ghrelin action
AU2001259056A1 (en) 2000-05-17 2001-11-26 Eli Lilly And Company Method for selectively inhibiting ghrelin action
EP1353683A4 (en) 2000-05-30 2004-05-12 Merck & Co Inc ANALOGS BY GHRELIN
US7629456B2 (en) * 2001-10-26 2009-12-08 Noxxon Pharma Ag Modified L-nucleic acid
EP1530635B1 (en) * 2002-08-01 2011-06-15 Noxxon Pharma AG Ghrelin binding nucleic acids
CN1894407A (zh) 2003-11-10 2007-01-10 诺松制药股份公司 特异性结合生物活性生长素释放肽的核酸
AR052741A1 (es) 2005-04-08 2007-03-28 Noxxon Pharma Ag Acidos nucleicos de union a ghrelin

Also Published As

Publication number Publication date
CN101189337A (zh) 2008-05-28
NL1033520A1 (nl) 2007-08-06
WO2006108599A3 (en) 2007-02-15
US8101734B2 (en) 2012-01-24
AU2006233647A1 (en) 2006-10-19
GT200600137A (es) 2006-11-22
CA2605377A1 (en) 2006-10-19
NL1031538C2 (nl) 2007-03-20
UY29460A1 (es) 2006-11-30
IL186085A0 (en) 2008-01-20
NL1031538A1 (nl) 2006-10-10
CN101189337B (zh) 2013-11-06
MA29384B1 (fr) 2008-04-01
US20120115937A1 (en) 2012-05-10
KR20080009072A (ko) 2008-01-24
WO2006108599A2 (en) 2006-10-19
AP2007004189A0 (en) 2007-10-31
EP1866412A2 (en) 2007-12-19
JP5308813B2 (ja) 2013-10-09
US20060258607A1 (en) 2006-11-16
MX2007012419A (es) 2007-12-05
NL1033520C2 (nl) 2010-01-21
TNSN07375A1 (fr) 2009-03-17
CR9423A (es) 2007-12-17
TW200718781A (en) 2007-05-16
PE20061358A1 (es) 2007-01-13
BRPI0608180A2 (pt) 2009-11-17
JP2008534024A (ja) 2008-08-28
GB0719489D0 (en) 2007-11-21
JP2013176372A (ja) 2013-09-09
AR052741A1 (es) 2007-03-28
AU2006233647A2 (en) 2008-04-17
GB2439673A (en) 2008-01-02
DOP2006000085A (es) 2006-11-15

Similar Documents

Publication Publication Date Title
EA200701901A1 (ru) Нуклеиновые кислоты, связывающие грелин
SI3222724T1 (sl) Nadaljnje nove oblike molekul interferenčne RNA
EA200800838A1 (ru) Модуляция иммуностимулирующих свойств короткой интерферирующей рибонуклеиновой кислоты (siphk) с помощью модификации нуклеотидов
DE50206993D1 (de) Verfahren zur hemmung der expression eine zielgens
EP1569695A4 (en) ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
EP2631293A3 (en) Human microRNAs and methods for inhibiting same
JP2014526899A5 (ru)
DE69133018D1 (de) Methoden zur zielrichtung von dna
ATE400650T1 (de) Verfahren zur herstellung von nukleinsäuremolekülen
MX2009000656A (es) Acidos nucleicos que se fijan a sdf-i.
ATE431407T1 (de) Verfahren zur herstellung von dna
WO2003097834A3 (en) A method for in vitro molecular evolution of protein function
DE602005022443D1 (de) Schnelle synthese von oligonukleotiden
DE60113277D1 (de) Verfahren zur herstellung von dicarbonsäurediarylestern
EP1333089A4 (en) SYNTHESIS METHOD FOR SINGLE STRANDED NUCLEIC ACID
DE60123334D1 (de) Methode für die Produktion von Nukleotiden durch Fermentierung
ATE409027T1 (de) Magensaftresistente salze von ketosäuren und aminosäuren und ihre verwendung zur herstellung von medikamenten
DE50214936D1 (de) Verwendung des adenoviralen e2-late-promotors
ES2190866B1 (es) Metodo para la insercion eficiente en sitios especificos de cualquier adn diana de intrones del grupo ii.
RU2004136207A (ru) Фрагмент днк, кодирующий синтез фитазы phy a, и фитаза phy a из бактерий obesumbacterium proteus